Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2046 of 6351
-
New radiation approach aims to tame sarcoma with fewer sessions
Disease control OngoingOne of the main challenges in treating sarcomas with radiation is the toxicity to normal structures around the sarcoma. Early reports suggest Hypofractionated Radiotherapy will be safe and effective for treatment of soft tissue sarcomas. However, given the rarity of this disease,…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Real-World dupixent: does it live up to the hype for eczema?
Knowledge-focused OngoingPrimary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To charact…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy duo takes on tough tumors
Disease control CompletedThis study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatm…
Phase 2 • Sponsor: John L. Villano, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo approach for breast cancer: reconstruction and radiation together
Disease control CompletedProspective, multicentric, non-randomized phase II study evaluating the surgical treatment by mastectomy with immediate prosthetic breast reconstruction in patients with breast cancer and receiving adjuvant therapy by TomoTherapy +/-Chemotherapy. Patients with non-inflammatory a…
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo targets rare BRAF mutations in advanced cancers
Disease control OngoingThis is a single-centre, open-label Phase II study of the investigational drugs binimetinib and encorafenib that will be taken my mouth (orally) daily in adult patient with advanced and/or metastatic solid tumors for which no other standard therapy is available. The main purpose …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
4-Year arthritis drug study shows promise for kids
Disease control CompletedOptional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo therapy aims to keep advanced lung cancer in check
Disease control OngoingThis is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or olaparib in participants with Extensive-Stage Disease Small Cell Lung Cancer (ES-SCLC) who hav…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Zapping the brain to quiet diabetic nerve pain
Symptom relief OngoingThe purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.
Sponsor: Case Western Reserve University • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New vaccine aims to shield seniors from dangerous e. coli infections
Prevention CompletedThe purpose of this study is to assess the safety, reactogenicity, and immunogenicity of 3 different doses of ExPEC10V and to select the optimal dose for further clinical development (Cohort 1). Cohort 2 is aimed to expand the dataset supporting the short- and long-term safety an…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
Could a viagra drug help fight liver cancer? new trial tests unlikely combo
Disease control Stopped earlyBackground: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver. Researchers want to study if a combination of drugs helps people with these cancers. The drugs are nivoluma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Custom video may ease brain tumor radiation anxiety
Symptom relief Recruiting nowThis trial studies whether a customized video intervention can help to reduce anxiety in brain cancer patients undergoing radiation treatment and their caregivers. A customized neuro-imaging referenced symptom video that describes symptoms and side effects specific to the patient…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
New cream shows promise for rare skin condition
Disease control CompletedCutaneous microcystic lymphatic malformations (CMLMs) are rare conditions of children and adults resulting from abnormal embryologic development of lymphatic vessels. They present as clusters of vesicles full of lymph and blood of various extent. They ooze and bleed, inducing mac…
Phase 2 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Hope for Hard-to-Treat Self-Injury: new behavioral approaches under study
Symptom relief OngoingAt least one quarter of the 18 million persons in the US with intellectual and developmental disabilities engage in self-injurious behavior (SIB), which can result in injuries, disfigurement, and loss of function (e.g., blindness). SIB that persists in the absence of social reinf…
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
New fluid strategy aims to reduce organ failure in septic shock
Disease control CompletedMany observational studies have highlighted an independent association between fluid overload and clinical outcomes during septic shock. To optimize fluid balance, clinician has several options to consider carefully fluid administration and avoid fluid overload. More than a gener…
Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 26, 2026 18:50 UTC
-
New hope for kidney cancer: targeted pill aims to stop tumor growth
Disease control Recruiting nowSingle arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New daily pill could tame ulcerative colitis in japanese patients
Disease control CompletedJapanese patients with moderate or severe active ulcerative colitis as a subject when ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy and safety with placebo as a control.
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could an antibody tame inflammation in kidney patients?
Disease control CompletedPatients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses …
Phase 2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Mindfulness may keep psychosis at bay
Prevention CompletedPracticing mindfulness is popular and well-accepted for its benefits in improving mental and physical health. In particular, its benefits in promoting resilience to stress and well-being have been shown in studies involving different psychiatric conditions, as well as preventing …
Sponsor: The University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 12:34 UTC
-
Can a plastic meniscus implant keep knees Pain-Free for years?
Disease control Stopped earlyThe purpose of this active post-market surveillance clinical registry study is to further characterize the therapeutic effect, the long-term safety and effectiveness of the NUsurface® meniscus implant in the real-world post-marketing setting
Sponsor: Phoenix Kinetics • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
A new study mines health data to spot painkiller dependence early
Knowledge-focused CancelledAbuse of analgesics represents an important part of prescription drug abuse. The consequences in terms of morbidity and mortality at the population level could reach worryingly high levels, as illustrated by the US context. This issue should not focus only on opioid analgesics, b…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC